Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Aug 2009

Nyman Heidi, Jerkeman Mats, Karjalainen-Lindsberg Marja-Liisa, Banham Alison H, Leppä Sirpa

Abstract excerpt

Gene expression profiling studies initially enabled diffuse large B-cell lymphoma to be divided into germinal center and activated B-cell-like subtypes, which define high- and low-risk patient groups when treated with chemotherapy. Attempts to reproduce the prognostic classification immunohistoch...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Rituximab
Share to Antibodies, Monoclonal, Murine-Derived

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Interferon Regulatory Factors

Share to Neprilysin

Share to Prednisolone

Share to Proto-Oncogene Proteins c-bcl-6

Share to Vincristine

Source

Identifiers

PMID: 19448593
DOI: 10.1038/modpathol.2009.73

Genes

FOXP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19448593-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.PMID 19448593Read ↗

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.Semantic proximity Read ↗

Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma.Semantic proximity Read ↗

Immunohistochemical and Molecular Characteristics with Prognostic Significance in Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Immunohistochemical profiling based on Bcl‐2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphomaSemantic proximity Read ↗

The significance of FOXP1 in diffuse large B-cell lymphoma.Semantic proximity Read ↗

FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomasSemantic proximity Read ↗

Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1Semantic proximity Read ↗

Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With RituximabSemantic proximity Read ↗

Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.Semantic proximity Read ↗

FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.Semantic proximity Read ↗

Prognostic impact of C-REL expression in diffuse large B-cell lymphomaSemantic proximity Read ↗

FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.